Lakefront Biotherapeutics (LKFT) Total Non-Current Liabilities (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Total Non-Current Liabilities for 13 consecutive years, with $21.2 million the latest figure, recorded in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 97.77% year-over-year to $21.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.2 million (down 97.77% YoY) and the FY2025 annual result came in at $20.2 million, down 98.03% from the prior year.
• Total Non-Current Liabilities grew to $21.2 million in Q1 2026 per LKFT's latest filing, from $20.2 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for LKFT reached as high as $2.2 billion in Q1 2022 and fell as low as $20.2 million in Q4 2025.
• A 5-year average of $1.1 billion and a median of $1.1 billion in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities fell 15.0% — and 2025, when it sank 98.03%.
• Year by year, Total Non-Current Liabilities stood at $1.9 billion in 2022, then plunged by 32.76% to $1.3 billion in 2023, then slipped by 20.28% to $1.0 billion in 2024, then slumped by 98.03% to $20.2 million in 2025, then gained by 4.77% to $21.2 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $21.2 million, $20.2 million, and $794.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.